Drug Type Small molecule drug |
Synonyms [14C]Lorlatinib, Lorlatinib (JAN/USAN/INN), 劳拉替尼 + [7] |
Target |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (21 Sep 2018), |
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN) |
Molecular FormulaC21H19FN6O2 |
InChIKeyIIXWYSCJSQVBQM-LLVKDONJSA-N |
CAS Registry1454846-35-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11012 | Lorlatinib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | US | 02 Nov 2018 | |
Non-Small Cell Lung Cancer | JP | 21 Sep 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ganglioneuroblastoma | Phase 3 | US | 14 May 2018 | |
Ganglioneuroblastoma | Phase 3 | CA | 14 May 2018 | |
Ganglioneuroblastoma | Phase 3 | PR | 14 May 2018 | |
metastatic non-small cell lung cancer | Phase 2 | US | 18 Dec 2015 | |
metastatic non-small cell lung cancer | Phase 2 | JP | 18 Dec 2015 | |
metastatic non-small cell lung cancer | Phase 2 | AU | 18 Dec 2015 | |
metastatic non-small cell lung cancer | Phase 2 | KR | 18 Dec 2015 | |
metastatic non-small cell lung cancer | Phase 2 | ES | 18 Dec 2015 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | 08 Jan 2014 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | JP | 08 Jan 2014 |
Phase 1 | 1 | cdapyfsbfa(mnddmdjbsm) = fqgfsautwo abgqvezqxd (yyyagqhokx, dxtkkclxwn - rfbiwhurbx) View more | - | 21 Jun 2024 | |||
Phase 3 | ALK positive Non-Small Cell Lung Cancer First line | 296 | (With Baseline Brain Metastases) | pgxsvuoxql(ndgyhxphki) = zaxbvywqsm mvonjmmdlx (gjhvjvuszj, 32.9 - NR) View more | Positive | 02 Jun 2024 | |
(With Baseline Brain Metastases) | pgxsvuoxql(ndgyhxphki) = vnbmufzojh mvonjmmdlx (gjhvjvuszj, 3.7 - 7.6) View more | ||||||
NCT03612154 (ASCO2024) Manual | Phase 2 | 32 | djczvoqflo(sgdaqiwynr) = hklwhedkmo izgcmozcgn (lxbbxnneil, 52 - 83) View more | Positive | 24 May 2024 | ||
Lorlatinib 100mg (treatment naïve) | djczvoqflo(sgdaqiwynr) = pnfrblxpte izgcmozcgn (lxbbxnneil ) View more | ||||||
Not Applicable | 43 | fbasairaxy(wurlwjatsk) = qoaimpyzjo flpifegvxj (qhtxdhosoe ) View more | Positive | 22 Mar 2024 | |||
Phase 2 | 6 | zgagsehwnk(uwgbzvqncu) = dxxcrwdzwv tdnmakzkmv (sokmpvykbc, 0.6 - 1.0) | - | 11 Dec 2023 | |||
ESMO2023 Manual | Not Applicable | 1,147 | zhaqenzdth(fngwnvmolk) = hvgjoomsgd cubdcpddid (ygwfylhams, 8.40 - 22.73) View more | Positive | 23 Oct 2023 | ||
(clinical trials) | zhaqenzdth(fngwnvmolk) = puzzfrxjlr cubdcpddid (ygwfylhams ) View more | ||||||
NCT03909971 (WCLC2023) Manual | Phase 2 | ALK positive Non-Small Cell Lung Cancer ALK Positive | 109 | kozbomkakb(gmodhtqbwl) = glcbsbbgow fxbqmoftau (ezktttgakt ) View more | Positive | 10 Sep 2023 | |
(cohort 1 + ALK-positive locally advanced or metastatic NSCLC and disease progression after crizotinib as the only ALK inhibitor) | shtmwqnhpv(lbrnqgqglx) = klysnbjelb eqagsugkut (wnizfkamon, 46.9 - 77.9) View more | ||||||
Phase 3 | 296 | gbwxqtgebf(dloiwufztz) = glhzngzpja gxhqatpzvc (hvdfnkvuxi ) View more | - | 12 Jun 2023 | |||
gbwxqtgebf(dloiwufztz) = gwwkpasnce gxhqatpzvc (hvdfnkvuxi ) View more | |||||||
Phase 3 | 296 | ufyykmjupp(ginxoqeeok): HR = 0.5 (95% CI, 0.23 - 1.12) View more | - | 07 Jun 2023 | |||
Phase 1 | 65 | kgkjkbvkwu(mxgezfatsh) = kseuqnxwqk lcvhfowfjl (mramjbhauo ) View more | - | 03 Apr 2023 | |||
kgkjkbvkwu(mxgezfatsh) = ysfuqhxzgl lcvhfowfjl (mramjbhauo ) View more |